Navigation Links
Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 Program
Date:10/14/2009

ost=http%3A%2F%2Fpowerlink%2Epowerstream%2Enet&w=349&h=400&clip=1&contID=MatrixTrial&bypass=">click here to view a television segment featuring an investigator in the study, Dr. Peter A. Blume of the Yale University School of Medicine, and click here to view a segment featuring Dr. Barbara Aung of the Aung Foothealth Clinics, and their patients enrolled in the Matrix clinical study. The Matrix study media segments can also be accessed at www.cardiumthx.com.

Matrix Phase 2b Clinical Study

The Matrix Phase 2b clinical study was a multi-center U.S.-based study designed to evaluate Excellarate for the potential treatment of non-healing diabetic foot ulcers. Enrollment in the study was ended early after key efficacy measures among blinded groups were observed at rates substantially higher than those expected for patients receiving only standard of care. The study, which was conducted at 20 medical centers, evaluated patients that were treated with the gene-activated Excellarate product candidate (Ad5PDGF-B / 2.6% collagen) or the collagen matrix component of Excellarate, compared to patients who received only standard of care treatment without any applied Ad5PDGF-B or collagen. A per protocol data analysis included 113 patients with lower extremity neuropathic ulcers that were chronically non-healing despite receiving standard of care. Eleven additional patients who were initially recruited into the trial were excluded (7 patients were lost to evaluation or had a disqualifying surgical procedure and 4 were determined to have been mis-enrolled based on prespecified enrollment criteria,
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot Ulcers
2. Scientific Journal Gene Therapy Reports That Cardiums Gene Activated Matrix Technology Accelerates Periodontal Tissue Regeneration
3. Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments
4. Cardium Completes Sale of InnerCool Therapies Business to Royal Philips Electronics
5. Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) Index
6. Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting
7. Cardium Reports on First Quarter 2009 Financial Results and Recent Developments
8. Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing Applications
9. Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE Amex
10. Cardiums InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapys Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury Patients
11. Cardium Reports on Recent Highlights, Financial Results and 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... News) -- There,s no genetic evidence that high levels ... new study says. Some previous research had suggested ... against type 2 diabetes, raising the possibility of a ... disease. In this study, British researchers investigated the ... on genes that control blood levels of vitamin D. ...
(Date:9/30/2014)... for doctors to measure damaging "brain tsunamis" in ... a step closer to reality, thanks to pioneering ... Institute. , The research team, led by Jed ... of neurosurgery at the UC College of Medicine, ... through an injured brain like tsunami wavescan be ...
(Date:9/30/2014)... 30, 2014 Keystone Symposia will convene the first ... its 2014-15 Global Health Series on "The Modes ... Hotel immediately following the conclusion of the Grand ... is part of the Keystone Symposia Global Health Series, ... has also funded travel awards for 36 investigators from ...
(Date:9/30/2014)... Federally Qualified Health Centers (FQHCs) granted new ... at higher rates than other primary care practices ... according to results of a new 10-state University ... Medical Care . , Using data from a ... 2013, the investigators found that FQHCs community ...
(Date:9/30/2014)... EverStryke , the permanent match currently offered by ... a free book and class all about survival education and ... investigative review. , “Joe Marshall of SurvivalLife.com is one ... niche, and this product is an excellent way to get ... that Joe offers on his website to help people be ...
Breaking Medicine News(10 mins):Health News:Gene Study Finds No Proof Vitamin D Guards Against Type 2 Diabetes 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2
... research published in the December issue of the ... that the American College of Surgeons National Surgical Quality ... assessing outcomes of uncommon, high-risk surgical procedures, including pancreatic ... on this particular procedure has been available and analyzed, ...
... finding a cure for amyotrophic lateral sclerosis (ALS, or ... to help more researchers identify treatment candidates that increase ... The Jackson Laboratory will provide the most widely used ... work with them, to researchers participating in the Prize4Life ...
... ... getting recommended eye exam; EyeSmart: EyeCommitted social media campaign seeks to reduce the largest ... ... more new cases of legal blindness among working-age Americans than any other disease. If ...
... , ST. LOUIS, Dec. 10 Centene Corporation (NYSE: ... release its 2010 financial guidance at approximately 6:00 AM (Eastern ... call afterwards at approximately 8:30 AM (Eastern Time) to discuss ... Chief Executive Officer, and William N. Scheffel, Executive Vice President, ...
... , CINCINNATI, Dec. 10 Streamline Health Solutions, ... document workflow solutions for hospitals, today announced that St. ... Health to provide a workflow solution to ensure compliance ... (VPP) promotes effective worksite-based safety and health. St. Vincent,s ...
... ... Home Care as well as one system encompassing virtually every clinical, operational and financial aspect ... , ... 10, 2009 -- Fastrack Healthcare Systems announced today the completion of the first phase ...
Cached Medicine News:Health News:Surgical quality program is a strong tool for assessing outcomes for high-risk procedures 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 2Health News:Prize4Life and the Jackson Laboratory team up to fight ALS 3Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 2Health News:Daniel Simon, MD Urges People with Diabetes to Protect Sight by Getting Diabetic Eye Exam 3Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 2Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 3Health News:Ascension Health Hospital Awards Streamline Health Contract to Ensure OSHA Compliance 4Health News:Fastrack Announces Major Expansion 2Health News:Fastrack Announces Major Expansion 3
(Date:9/30/2014)... 30, 2014 Valeant Pharmaceuticals International, Inc. (NYSE: ... that the company,s Bridgewater, New Jersey ... Food and Drug Administration (FDA) relating to an inspection ... to Sculptra Aesthetic injectable, which was divested to Galderma ... management of Valeant,s contract manufacturers (rather than Valeant,s own ...
(Date:9/30/2014)... 30, 2014 The Eastern European medical device ... providers as well as new medical-device manufacturers are constantly ... looking at ways to reduce the cost incurred for ... one of the effective means to achieve this target. ... in Eastern European and provides profiles of key distributors ...
(Date:9/30/2014)... Sept. 30, 2014   Decision Resources Group ... data, anemic chronic kidney disease non-dialysis (CKD-ND) patients ... (ESA) medication. In addition, one-year persistency is similar ... Other key findings from the report entitled ... of Erythropoiesis Stimulating Agents in Late Stage Chronic ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... on 01/05/2012 of Santa Barbara physician Dr. Julio Diaz ... overdose deaths from prescription medications. According to one of ... centers, Dr. Diaz,s arrest points to the dangers both ... of finding a physician who will prescribe medication for ...
... PHILADELPHIA, January 10, 2012 Shire plc (LSE: ... company, announced today that it has acquired the rights to ... States (US) in an agreement  with Janssen Pharmaceutica N.V.  Terms ... a prokinetic, is part of Shire,s gastrointestinal (GI) portfolio in ...
Cached Medicine Technology:Arrest of California Doctor Coincides with Uptick in Prescription Drug Overdoses 2Shire Acquires US Rights to Resolor® (prucalopride) 2Shire Acquires US Rights to Resolor® (prucalopride) 3Shire Acquires US Rights to Resolor® (prucalopride) 4
The extended lip of the lower jaw assists in placing the lower jaw underneath less-mobile menisci....
The Smith & Nephew ACUFEX DUCKLING punches are a lower-profile relation to the Duckbill, maintaining a large square bite and maximizing maneuverability....
For the specific requirements of the posterior horn of the meniscus; the short, low profile jaw facilitates working in the tight confines of the posterior aspect of the knee....
The narrow shaft and compact jaw design facilitates access and use in tight spaces, particularly useful in the posterior aspect of the knee....
Medicine Products: